tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2022 Oct;28(13):85-92.
doi: 10.3201/eid2813.220780.
Determining Gaps in Publicly Shared SARS-CoV-2 Genomic Surveillance Data by Analysis of Global Submissions
Elizabeth C Ohlsen, Anthony W Hawksworth, Kimberly Wong, Sarah Anne J Guagliardo, James A Fuller, Michelle L Sloan, Kevin O'Laughlin
Abstract
Viral genomic surveillance has been a critical source of information during the COVID-19 pandemic, but publicly available data can be sparse, concentrated in wealthy countries, and often made public weeks or months after collection. We used publicly available viral genomic surveillance data submitted to GISAID and GenBank to examine sequencing coverage and lag time to submission during 2020-2021. We compared publicly submitted sequences by country with reported infection rates and population and also examined data based on country-level World Bank income status and World Health Organization region. We found that as global capacity for viral genomic surveillance increased, international disparities in sequencing capacity and timeliness persisted along economic lines. Our analysis suggests that increasing viral genomic surveillance coverage worldwide and decreasing turnaround times could improve timely availability of sequencing data to inform public health action.
Keywords: COVID-19; SARS-CoV-2; coronavirus disease; pandemic; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine-preventable diseases; viral surveillance; viruses; zoonoses.
. 2022 Oct;28(13):85-92.
doi: 10.3201/eid2813.220780.
Determining Gaps in Publicly Shared SARS-CoV-2 Genomic Surveillance Data by Analysis of Global Submissions
Elizabeth C Ohlsen, Anthony W Hawksworth, Kimberly Wong, Sarah Anne J Guagliardo, James A Fuller, Michelle L Sloan, Kevin O'Laughlin
- PMID: 36502409
- DOI: 10.3201/eid2813.220780
Abstract
Viral genomic surveillance has been a critical source of information during the COVID-19 pandemic, but publicly available data can be sparse, concentrated in wealthy countries, and often made public weeks or months after collection. We used publicly available viral genomic surveillance data submitted to GISAID and GenBank to examine sequencing coverage and lag time to submission during 2020-2021. We compared publicly submitted sequences by country with reported infection rates and population and also examined data based on country-level World Bank income status and World Health Organization region. We found that as global capacity for viral genomic surveillance increased, international disparities in sequencing capacity and timeliness persisted along economic lines. Our analysis suggests that increasing viral genomic surveillance coverage worldwide and decreasing turnaround times could improve timely availability of sequencing data to inform public health action.
Keywords: COVID-19; SARS-CoV-2; coronavirus disease; pandemic; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine-preventable diseases; viral surveillance; viruses; zoonoses.